Webinar: Generating Fully Human Antibodies and Antibody-based Therapeutics with RenMab, RenLite & RenNano Mice
Our webinar “Generating Fully Human Antibodies and Antibody-based Therapeutics with RenMabTM, RenLiteⓇ & RenNanoTM Mice” was live at 1:00 PM EDT on June 20th, 2023.
About the Webinar
Therapeutic development of antibodies and antibody-based drugs is a multi-year process that involves high cost and significant risk. In recent years, a common discovery approach to ensure the quality of new anti-human therapeutic antibodies is to express select human immunoglobulin genes in mice. In this webinar, we will highlight the advantages of therapeutic discovery using RenMabTM mice, which were engineered to contain the entire human immunoglobulin variable region in situ. Similarly, second-generation models (RenLiteⓇ and RenNanoTM mice) offer specialized solutions for the discovery of bispecific/multispecific antibodies or nanobodies. Finally, case study data will showcase the advantages of working with Biocytogen’s antibody discovery service team to accelerate discovery for your target or targets of interest.
Speaker
Li Hui, MD, PhD
Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston
Moderator
Jenna Frame, PhD
Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston
Panelist
Qingcong Lin, PhD. Chief Executive Officer, Biocytogen Boston
Watch the webinar recording: Generating Fully Human Antibodies and Antibody-based Therapeutics with RenMab, RenLite & RenNano Mice
